New Treatments in Chronic Rhinosinusitis with Nasal Polyps: Expert Insights into the Evidence

Released On
April 28, 2021

Expires On
April 28, 2022

Media Type
Internet

Completion Time
75 minutes

Specialty
Allergists, Otolaryngologists (ENT’s), Rhinologists, Primary Care/Family Medicine/Internal Medicine Physicians

Topic(s)
Allergies

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by National Jewish Health.

This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of allergists, otolaryngologists (ENTs), rhinologists, primary care/ family medicine/internal medicine physicians and advanced practice providers who diagnose and treat allergic and pulmonary diseases.

Program Overview

Chronic rhinosinusitis (CRS) is a complex inflammatory disorder, with multiple clinical phenotypes, affecting approximately 10% of adults in the United States (US). Patients with CRS with nasal polyps (CRSwNP) have a more clinically severe form of the disease, which has a substantial negative impact in health-related quality of life. The goal of this educational activity is to improve clinicians’ knowledge and competence within the educational gaps of diagnosis, management, and treatment of CRSwNP. To optimize the outcomes of patients with CRSwNP, this activity will address clinical features of the disease, its pathophysiology and immunology, strategies for longitudinal multidisciplinary management, and current and emerging therapies for optimal individualized treatment plans.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe clinical features and key concepts in the pathophysiology and immunology of CRSwNP.
  • Evaluate strategies for longitudinal management using a multidisciplinary approach.
  • Discuss current and emerging therapies and treatment selection based on patient inflammatory phenotype, comorbidities and other individual factors.

Faculty

FACULTY_NAME

Daniel Beswick, MD

Assistant Professor-in-Residence
University of California Los Angeles
Los Angeles, CA
Adjunct Assistant Professor
National Jewish Health
Denver, CO

FACULTY_NAME

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy & Clinical Immunology
Department of Medicine
National Jewish Health
Denver, CO

 

Physician Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Education.

Faculty

Daniel Beswick, MD

  • Consultant: Medtronic

Eileen Wang, MD, MPH

  • Consultant: AstraZeneca
  • Investigator: Genentech, GlaxoSmithKline and OPC

Planners and Reviewers

Harold Nelson, MD; Meghan Brenner, MA; Andrea Harshman, MHA, CHCP, CMP-HC; and Mandy Comeau have no relevant financial relationships to report.

Method of Participation

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test with a minimum score of 2 out of 3
  4. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

National Jewish Health requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions, please contact: National Jewish Health at: Proed@NJHealth.org

Contact this CME provider, National Jewish Health, for privacy policy statement information at: https://www.nationaljewish.org/education/pro-ed/policies

Resources

Click to view the following resources:
Clinical Reference Aid

Downloadable Slide Deck